UCB's Global Corporate Website

Treating-to-target in autoimmune diseases

Posted by
Ivo Huybrechts, Global Medical Education - Medical Immunology Europe
17-Mar-2014
At UCB, our scientists have been working to deepen our understanding of immunology and the inflammatory system for decades. This work, in collaboration with scientists around the world, has delivered new therapies for severe autoimmune diseases that can make a real difference to people’s lives.

Of course, science moves quickly. So we facilitate the sharing of the most recent scientific knowledge among healthcare professionals by supporting medical educational meetings and conferences.

Last weekend (15-16 March), over 450 healthcare professionals from 36 countries attended the fifth UCB-sponsored International Immunology Summit in Prague. The meeting was chaired by Professor Maxime Dougados, Professor of Rheumatology, Paris.

The overarching theme for this year focused on ‘Treating-to-Target in Autoimmune Diseases’, a patient-centric approach which strives to reach the target of remission or low disease activity in every patient as quickly as possible.

The Summit covered educational topics on a range of autoimmune conditions including rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), systemic lupus erythematosus (SLE) and osteoporosis.

With 49 distinguished speakers, 21 disease-focused plenary sessions and an opening debate addressing the challenges of treating autoimmune diseases to target, delegates were given an intensive yet comprehensive update on current thinking in this field.

Additional mini-symposia examining topics such as family planning and pregnancy in immunological diseases (FPPi), management of bone disorders, and the translation of clinical trials into clinical practice were also popular with those in attendance.

Leave a Comment

By submitting your personal data, you agree with UCB's Data Privacy Policy. Furthermore, for more information on the terms of use of this website please visit our Legal Notice, accessible here.

CAPTCHA

Enter the characters shown in the image.